Related Experiment Video
Updated: Jun 11, 2025
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Identification of potential core genes in lung cancer and therapeutic traditional Chinese medicine compounds using
Yue Zhang1, Yaguang Wang2, Xuepu Zhang3
1The Second Affiliated Hospital of Jinzhou Medical University, Jinzhou, China.
Abstract:
Lung cancer (LC) remains the leading cause of cancer-related death. We identified potential therapeutic targets and traditional Chinese medicine (TCM) compounds for LC treatment. GSE43346 and GSE18842 were derived from the Gene Expression Omnibus (GEO) database and used to identify differentially expressed genes (DEGs). Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed using The Database for Annotation, Visualization and Integrated Discovery (DAVID). Protein-protein interactions were analyzed using STRING and Cytoscape software. Hub gene expression was validated using Gene Expression Profiling Interactive Analysis and the Human Protein Atlas. Kaplan-Meier survival analysis was conducted to evaluate the prognostic value of hub genes in patients with LC. Therapeutic TCM compounds were screened using the Comparative Toxicogenomics Database, and DEGs were largely enriched in biological processes, including cell division and mitotic nuclear division, such as the cell cycle and p53 signaling pathways. Elevated expression of hub genes was observed in LC samples. Overexpression of CDC20, CCNB2, and TOP2A is an unfavorable prognostic factor for postprogressive survival in patients with LC. Paclitaxel, quercetin, and rotenone have been identified as active substances in TCM. CDC20, CCNB2, and TOP2A are novel hub genes associated with LC. Paclitaxel, quercetin, and rotenone can be used as therapeutic agents in TCM.
Insights
This study identifies novel lung cancer (LC) therapeutic targets, CDC20, CCNB2, and TOP2A, and potential traditional Chinese medicine (TCM) treatments like paclitaxel. These findings offer new avenues for LC treatment strategies.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Lung cancer (LC) is a leading cause of cancer mortality.
- Identifying novel therapeutic targets and treatments is crucial for improving patient outcomes.
Purpose of the Study:
- To identify differentially expressed genes (DEGs) and hub genes in lung cancer.
- To explore potential therapeutic agents from traditional Chinese medicine (TCM) for LC treatment.
Main Methods:
- Utilized GEO datasets (GSE43346, GSE18842) to identify DEGs.
- Performed pathway enrichment analysis (GO, KEGG) and protein-protein interaction analysis (STRING, Cytoscape).
- Validated hub gene expression and analyzed prognostic value using survival analysis.
Main Results:
- DEGs were enriched in cell cycle and p53 signaling pathways.
- Identified CDC20, CCNB2, and TOP2A as novel hub genes with elevated expression in LC.
- Overexpression of these hub genes is linked to unfavorable prognosis in LC patients.
- Screened paclitaxel, quercetin, and rotenone as potential TCM therapeutic agents.
Conclusions:
- CDC20, CCNB2, and TOP2A are novel prognostic biomarkers for lung cancer.
- Paclitaxel, quercetin, and rotenone show promise as TCM-based therapeutic agents for LC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...